Cytomx Therapeutics, Inc. (CTMX): Timothy M Shannon , director of Cytomx Therapeutics, Inc. sold 111,498 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $10.02 per share for a total value of $1,116,289.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 6, 2016, Timothy M Shannon (director) sold 59,621 shares at $10.81 per share price.On Oct 16, 2015, William Michael Kavanaugh (CSO, Head Res.&Non-Clin. Dev.) purchased 5,000 shares at $12.00 per share price.Also, On Oct 16, 2015, Frederick W Gluck (director) purchased 15,000 shares at $12.00 per share price.On Oct 16, 2015, Cynthia J Ladd (Senior VP and General Counsel) purchased 3,000 shares at $12.00 per share price.
CytomX Therapeutics Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company’s pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company’s additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.